CM-AT / Curemark - LARVOL DELTA

An Open Label Study of CM-AT for the Treatment of Children With Autism (clinicaltrials.gov) - P3 | N=405 | Active, not recruiting | Sponsor: Curemark | Trial completion date: Jan 2025 ➔ Jan 2028 | Trial primary completion date: Jan 2025 ➔ Jan 2028

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

Pancreatic Replacement Therapy for Maladaptive Behaviors in Preschool Children With Autism Spectrum Disorder. (PubMed, JAMA Netw Open) - P3 | "Our high-protease pancreatic replacement (CM-AT) was well tolerated with no emergent safety concerns or related serious adverse events noted...This delayed-start analysis, used to demonstrate disease and condition modification, may prove to be an important tool to evaluate treatments for ASD. ClinicalTrials.gov Identifier: NCT02410902 and NCT02649959."

Journal • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mental Retardation • Psychiatry

An Open Label Study of CM-AT for the Treatment of Children With Autism (clinicaltrials.gov) - P3 | N=405 | Active, not recruiting | Sponsor: Curemark | Trial completion date: Jun 2023 ➔ Jan 2025 | Trial primary completion date: Jan 2023 ➔ Jan 2025

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study) (clinicaltrials.gov) - P3 | N=190 | Completed | Sponsor: Curemark | N=335 ➔ 190

Enrollment change • Autism Spectrum Disorder • Genetic Disorders

An Open Label Study of CM-AT for the Treatment of Children With Autism (clinicaltrials.gov) - P3 | N=405 | Active, not recruiting | Sponsor: Curemark | Trial completion date: Jun 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2021 ➔ Jan 2023

Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

An Open Label Study of CM-AT for the Treatment of Children With Autism (clinicaltrials.gov) - P3; N=405; Active, not recruiting; Sponsor: Curemark; Trial completion date: Dec 2019 ➔ Jun 2022; Trial primary completion date: Dec 2019 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders